Inhibition of cough-reflex sensitivity by Benzonatate (cas 104-31-4) and guaifenesin in acute viral cough

Add time:08/15/2019    Source:sciencedirect.com

SummaryAcute cough due to viral upper respiratory tract infection (URI) is the most common form of cough and accounts for tremendous expenditure on prescription and non-prescription cough products worldwide. However, few agents have been shown in properly conducted clinical trials to be effective for cough due to URI. The present study evaluated the effect of Benzonatate (cas 104-31-4) 200 mg (B), guaifenesin 600 mg (G), their combination (B + G), and placebo (P) on capsaicin-induced cough in 30 adult nonsmokers with acute URI. On 3 separate days within a 7-day period, 1 h after ingesting randomly assigned study drug in a double-blind fashion, subjects underwent capsaicin cough challenge testing, which involved inhalation of incremental doubling concentrations of capsaicin until the concentration of capsaicin inducing 5 or more coughs (C5) was attained. Each subject received 3 of 4 possible study drugs. G (p = 0.01) but not B (p = NS) inhibited cough-reflex sensitivity (log C5) relative to P. The combination of B + G suppressed capsaicin-induced cough to a greater degree than B alone (p < 0.001) or G alone (p = 0.008). The mechanism by which the combination of B + G causes a potentiation of antitussive effect remains to be elucidated. Our results suggest that B + G may be an effective therapy for acute cough due to the common cold (URI).

We also recommend Trading Suppliers and Manufacturers of Benzonatate (cas 104-31-4). Pls Click Website Link as below: cas 104-31-4 suppliers

Prev:Degradation kinetics of Benzonatate (cas 104-31-4) in aqueous solutions
Next:Selected topic: ToxicologyCardiac Arrest With Residual Blindness After Overdose of Tessalon® (Benzonatate (cas 104-31-4)) Perles)